Recent Updates
Recently added Catalysts
ELDN Positive Sentiment

Tegoprubart Sustains Increased eGFR Longterm Compared to Tacrolimus

Key Takeaway: The article discusses the long-term efficacy of Tegoprubart in sustaining increased estimated Glomerular Filtration Rate (eGFR) compared to Tacrolimus. This finding suggests that Tegoprubart may offer better renal function outcomes for patients. The results highlight the potential benefits of Tegoprubart in clinical settings, particularly for organ transplant patients.
Price reaction · baseline $3.965 (2026-07-15T16:14:00.000Z) · hit during market hours · clean, no other ELDN news in the window
day 0 close · peak
+1.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Tegoprubart shows sustained increased eGFR long-term.
  • Comparison with Tacrolimus indicates better outcomes.
  • Potential for improved patient quality of life.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+90%
120-day peak, hindsight
Typical move
6.5%
average across 7 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
AT-1501
Phase 2 · Kidney Transplant Rejection

Full Press Release Details

Transforming Lives. One Organ at a Time.
• Overview Focus Patient Stories Clinical Trials In The News
• Science Mechanism of Action Pipeline Publications & Presentations In The News
• Team Overview Leadership Board of Directors
• Investors Overview News & Events Press Releases Events Publications & Presentations Corporate Governance Governance Overview Committee Composition Ethics Hotline Financials SEC Filings Stock Information Stock Quote & Chart Analyst Coverage Resources Investor FAQs Email Alerts Contact IR
• Culture/Careers Culture Careers
• Contact
• Focus
• Patient Stories
• Clinical Trials
• In The News
• Mechanism of Action
• Pipeline
• Publications & Presentations
• In The News
• Overview
• Leadership
• Board of Directors
• Overview
• News & Events Press Releases Events Publications & Presentations
• Corporate Governance Governance Overview Committee Composition Ethics Hotline
• Financials SEC Filings
• Stock Information Stock Quote & Chart Analyst Coverage
• Resources Investor FAQs Email Alerts Contact IR
• Press Releases
• Events
• Publications & Presentations
• Governance Overview
• Committee Composition
• Ethics Hotline
• SEC Filings
• Stock Quote & Chart
• Analyst Coverage
• Investor FAQs
• Email Alerts
• Contact IR
• Culture
• Careers
• Privacy Overview
• Necessary
• Analytics
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.

Frequently Asked Questions

What is Tegoprubart?

Tegoprubart is a medication evaluated for its effectiveness in improving kidney function.

How does Tegoprubart compare to Tacrolimus?

Tegoprubart has shown better long-term eGFR outcomes compared to Tacrolimus.

What are the benefits of Tegoprubart?

Tegoprubart may enhance renal function and improve patient quality of life.

What does eGFR stand for?

eGFR stands for estimated Glomerular Filtration Rate, a measure of kidney function.

Last updated: Jul 15, 2026